Xarelto (Rivaroxiban) has been the subject of many lawsuits from patients and family members of patients who suffered uncontrolled bleeding while taking the blood thinner drug.
Multiple studies have linked Xarelto to gastrointestinal bleeding and other incidences of uncontrolled bleeding. In fact, a study was published in BMJ in April 2015, examining the Xarelto gastrointestinal bleeding risk. The study examined over 46,000 participants who were evaluated as they switched from warfarin to Xarelto. It was found that they had a 200% increase in their risk of stomach bleeding.
Xarelto has also been associated with intestinal bleeding and colon bleeding, along with brain bleeds, kidney bleeds,
According to another study, the Xarelto internal bleeding risk was about 25% higher than while taking warfarin. In addition to this higher risk of bleeding, patients are also faced with the realization that there is no Xarelto antidote. Warfarin can be reversed with dosages of Vitamin K, while another new-generation anticoagulant sold under the name Pradaxa cannot be reversed, but an emergency round of dialysis can cleanse the drug from the patient’s system.
Not even aggressive, emergency dialysis can help patients who have taken Xarelto. Half life for the drug is between 5 and 9 hours for a healthy patient between the ages of 20 and 45; the half life for Xarelto is much longer in older patients. It’s those older patients who account for a large portion of the cases involving uncontrolled gastrointestinal bleeding.
Xarelto hemorrhaging incidents — especially those involving intestinal bleeding or stomach bleeding — have been found to be much more common in the elderly. A study that was unveiled at the 2015 annual scientific meeting of the American Geriatrics Society revealed that over 74% of the uncontrolled bleeding incidents involved patients over the age of 75 years. When it comes to fatal bleeds, the average patient age was 82 years.
New Study on Xarelto: Eye Bleeding a Risk
One new study that was recently released and published in JAMA Ophthalmology revealed that multiple patients were diagnosed with vitreous hemorrhage, which entails bleeding in the space between the eye’s retina and the optical lens. In that particular study, it was found that the patients had transitioned from the tried-and-true anticoagulant drug warfarin to the newer Xarelto and it was after this transition that the bleeds occurred.
Hundreds of Xarelto lawsuit cases are now in the court system, pending trial. A small number of cases have been settled, while dozens of others are awaiting their day in court. The Xarelto lawsuits have been compiled into a multi-district litigation (MDL) case, which is being handled by Judge Eldon Fallon. The courts are currently in the process of reviewing the cases and determining which will serve as bellwether cases.
If you’ve suffered uncontrolled bleeding while taking Xarelto, you could be eligible to receive compensation. You’re encouraged to contact the experienced legal team at The Meldofsky Law Firm to discuss your case in a free, confidential consultation. Call 877-274-8672.